The new reality of early‑phase diabetes trials
Diabetes drug development has changed more in the last 10 years than in the previous three decades combined. Indeed, today, diabetes is recognised as a broad metabolic disease with implications that extend far beyond glycaemia, rather than a condition controlled only by tracking glucose and insulin. And this shift has raised the stakes for early‑phase development.
Now, cardiovascular, renal, and hepatic health are considered, as well as sleep quality, systemic inflammation and, of course, body weight. Today’s new therapies look to demonstrate benefits across a much wider landscape, wherein other medications, comorbidities, and patient variability have an impact on results. This has led to a new model in which Phase I and Phase II thinking increasingly overlap.
Diabetes beyond glucose control: Metabolic syndrome and GLP-1 RAs
Journeying from SGLT2 inhibitors – there are four available in the UK (canagliflozin, dapagliflozin, empagliflozin, and ertuglifozin), but they cannot be prescribed to patients with diabetic ketoacidosis (DKA), though they still hold an important place in treatment of patients with heart failure or renal disease – to the first GLP-1 receptor agonists, from the US FDA's 2005 approval of incretin exenatide for clinical use to the FDA’s 2010 approval of liraglutide as the first once-daily GLP-1 RA: the path has been a long but eventually fruitful one, arriving at the multi-agonists of the last couple of years and today’s blockbusters from Eli Lilly and Novo. Indeed, GLP-1 RAs are now recommended as a first-line therapy for type 2 diabetes in patients with established cardiovascular disease and/or complications from obesity.
For Prof Dr Thomas Forst, chief medical officer at hVIVO, diabetes is now certainly much more than glucose control. Nonetheless, the wide-ranging benefits of GLP-1 RAs were eye-opening in the beginning.
“Starting with the SGLT 2 inhibitors, regulators asked us to run studies to prove the cardiovascular safety of new drugs for aimed for the treatment of Type 2 Diabetes.” Dr Forst recounted. “We were very surprised that it detected that they have beneficial effects, that we reduce cardiovascular complications like myocardial infarction, like stroke, and that also mortality was reduced in these patients.”
“Nowadays, we see diabetes from another perspective,” he continued. “Of course, glucose control still plays a role. It's not gone, but it is only one piece of the puzzle. And it's much, much more part of metabolic syndrome, where we have inflammation, where we have hypertension, where we have lipid disorders, and we have glucose control, we have insulin resistance, and a lot of others. This is associated with a huge number of comorbidities.”
“We see more and more new peptides, more and more new molecules and now we have these dual agonists, we have triple agonists,” Dr Forst said. “We are now also moving away from the peptides and we see the first oral drugs, which will be small molecules. These small molecules will not only offer easier application but also simplify manufacturing and handling of the drug.
A shift in mindset in early-phase development
Diabetes is no longer a single-metabolic disease, then, and the therapies emerging today demand a far more sophisticated early‑phase approach than ever before; one that recognises diabetes as a multi-system disease. With numerous drug candidates in preclinical and clinical development, sponsors will increasingly require multi‑system endpoints, sophisticated biomarker packages, cardiac safety oversight, metabolic profiling, and early‑phase study designs that anticipate downstream regulatory expectations.
“Development of new drugs [has been] a very, very slow process,” explained Dr Forst. “A classical Phase I looked into the safety of a new drug, the pharmacokinetics […] And when this was done, we moved over to the patients and started looking at efficacy, looking really also into the clinical endpoints, the pharmacodynamic endpoints. Nowadays, the industry wants to have that much faster to decide about further investments in a new drug candidate.” On the other hand regulators are also interested to see an early assessment of efficacy markers to avoid an unnecessary exposition of volunteers to an ineffective drug candidate.
“Big pharma wants to identify their best candidates very, very early,” Dr Forst continued. “They have a couple of drugs, a couple of molecules, which they need developed for obesity or obesity-related complications and, of course, they are interested in seeing very, early which are the strongest ones, which have the best efficacy, or they are even interested to see which are the weak ones to stop the programmes and not to invest too much money in a drug which will, at the end, have only moderate effects on the disease […] They want to have more speed in proof of concept or in proof of failure.”
“For the small biotechs, the driver is a little bit different,” he advised. “They need to find investors for the development […] and they need the signals to convince investors that they have a very effective drug.”
Such modern diabetes drug development requires a much more integrated environment to suit the new complexities.
“This is precisely the environment hVIVO’s early‑phase engine is built for,” noted Dr Forst. “Our teams work across cardiometabolic, infectious disease, immunology, and respiratory therapeutics, and we’ve seen firsthand how modern mechanisms behave across systems. We understand how to design early‑phase studies that capture the right signals, at the right time, with the right depth.”
“We still go into healthy volunteers, we still look into safety and pharmacokinetic data analysis, but we start much, much earlier with patient populations,” he continued. “And this is sometimes within one protocol, so that we have the healthy volunteer under one protocol and in the same protocol we also have the first patients in there. This makes protocols and clinical studies much, much more complex than in the past.”
“We are already looking in pre-diabetic patients to see what is effective,” Dr Forst said. “It starts with obesity, it starts with fat tissue, dysfunctional fat tissue, which then triggers the metabolic syndrome, triggers insulin resistance, triggers pre-diabetes, diabetes, and a lot of life treating comorbidities at the very end. But you might already see complications even before you have type 2 diabetes […] With these new drugs, the weight controlling drugs, we have beneficial effects not only on glucose control, [but] also on blood pressure, on lipid status, on inflammation status.”
With new complexities, new methodologies
It goes without saying that well-characterised patients are crucial to have access to, in order to have them participate in these studies.
“It’s not enough to to have thousands of obese , prediabetic and diabetic patients in your database’: you need to have well characterized patients with regard to comorbidities like fatty liver disease, blood pressure, lipids, cardiovascular diseases, or inflammation,” said Dr Forst. “If you don't know, you have to screen all the people again to see how many really fit into a certain study […]. “The other point [is] how we do that,” he continued. “We work closely together with a couple of physicians in our area. These are GPs or diabetologists in the main, and they help us to recruit and to identify the correct patients for the studies. So, it's not only our own database, we also have more than 50 GPs or diabetologists in our area who also screen their patient database and support us in our recruitment activities.”
The other aspect is the methodology.
“[If] you look into fat distribution, this might be DEXA machines, this might be MRI machines. You might have customers who are interested in the fat content in distinct body compartments like the liver, muscle, or the paracardial space. You might have costumers interested in tracking food intake or energy metabolism. You have to find a way how to measure it,” Dr Forst explained. “And you have to have the equipment […] or you need a partner where you can do these kind of measurements, some of which are very complicated, very scientific. You do not find them in every hospital, for example. So, we are working together with the radiology departments of universities, where they have special technologies to address these needs.”
“I believe we are at the very beginning, and the exciting thing is that we not only see new drugs, new ways to treat these comorbidities, but we also get a better understanding of the mechanisms and pathways beyond the disease. A fat cell is so much more than just a place where you store your triglycerides or your fat. It's a cosmos […] It's totally fascinating,” concluded Dr Forst.
About the interviewee
Professor Thomas Andreas Forst is Chief Medical Officer at hVIVO, serving at Clinical Research Services (CRS), part of the hVIVO Group, since 2018. Previously, he was CEO and Director for Medical Science at Profil Institute Mainz (2013-2018) and CEO and Medical Director of the Institute for Clinical Research and Development in Mainz (2001-2013). From 1999-2001, he served as Clinical Research Physician at Eli Lilly Indianapolis, overseeing clinical trials for cardiometabolic disease treatments. A board-certified physician specialising in internal medicine and endocrinology, Professor Forst began his career in 1989 at the German Diabetes Research Institute. He joined Johannes Gutenberg University in Mainz in 1991, earning credentials in Internal Medicine (1996) and Endocrinology (1997). Appointed Professor of Internal Medicine in 2006, he continues training medical students today.
About hVIVO
hVIVO plc (Ticker: HVO) is a science‑led early‑phase drug development company purpose‑built to meet the growing complexity of modern clinical research. The Company operates an integrated early‑phase ecosystem that combines specialist clinical sites, advanced virology and immunology laboratories, human challenge expertise, and early drug development consulting. This unified model enables sponsors to generate rigorous, decision‑ready human data earlier in development, reducing uncertainty and accelerating progression through Phase I and II trials.
With industry‑leading capabilities in respiratory and infectious disease, alongside expanding expertise in cardiometabolic and other high‑growth therapeutic areas, hVIVO supports a diverse global client base that includes seven of the world’s ten largest biopharmaceutical companies. Its London quarantine facilities are the largest purpose‑built human challenge units in the world, complemented by additional early‑phase clinical capacity in Germany and a specialist consulting team providing strategic, regulatory, and biometry expertise.
The Company’s integrated approach delivers a seamless pathway from preclinical planning through early proof‑of‑concept, supported by continuous patient recruitment through FluCamp and a network of outpatient clinical sites for Phase II and III studies. By unifying scientific insight, operational control, and advanced laboratory capabilities, hVIVO provides sponsors with the clarity, speed, and reliability required to advance new medicines with confidence.
